首页> 外文OA文献 >Erratum to: The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer

【2h】

Erratum to: The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer

机译：错误：彗星开放标签II研究Neoadjuvant Folfox或Xelox治疗结合分子靶向单克隆抗体在结直肠癌的可重置肝转移患者中

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

AI期刊论文写作 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Masato Kataoka; Mitsuro Kanda; Kiyoshi Ishigure; Hiroshi Matsuoka; Yusuke Sato; Takao Takahashi; Chihiro Tanaka; Tomohiro Deguchi; Yoshihisa Shibata; Mikinori Sato; Hitoshi Inagaki; Takanori Matsui; Akinobu Kondo; Nao Takano; Haruyoshi Tanaka; Junichi Sakamoto; Koji Oba; Ken Kondo;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer [J] . Masato Kataoka, Mitsuro Kanda, Kiyoshi Ishigure, Annals of surgical oncology . 2017,第2期

机译：彗星开放标签期II研究Neoadjuvant Folfox或Xelox治疗结合分子靶向单克隆抗体在结直肠癌的可重症肝转移患者中
2. FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial [J] . Hebbar M., Chibaudel B., Andre T., Annals of oncology: official journal of the European Society for Medical Oncology . 2015,第2期

机译：可切除的转移性结直肠癌（MIROX）患者中FOLFOX4与序贯剂量密集型FOLFOX7继之以FOLFIRI的比较：一项开放性随机III期临床试验的一种实用的化疗围手术期或术后化疗时机方法
3. FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial (vol 26, pg 340, 2015) [J] . Hebbar M., Chibaudel B., Andre T., Annals of oncology: official journal of the European Society for Medical Oncology . 2015,第5期

机译：可切除的转移性结直肠癌（MIROX）患者中的FOLFOX4与序贯剂量密集型FOLFOX7继之以FOLFIRI：从开放标签，随机III期试验（第26卷，第340页，2015年）进行围手术期或术后化疗的化疗时机的实用方法）
4. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status [O] . Thierry André, Timothy Iveson, Roberto Labianca, -1

机译：IDEA（国际辅助化疗持续时间评估）合作：III期试验的前瞻性联合分析研究针对III期结肠癌患者的FOLFOX（FOLFOX4或改良的FOLFOX6）或XELOX（3个月至6个月）方案的辅助治疗的持续时间的III期试验：试验设计与现状
5. 03:18 PM Abstract No. 104 Irinotecan drug-eluting beads chemoembolization (DEBIRI) plus mFolfox6 as front-line treatment in patients with non resectable liver dominant metastases of colorectal cancer (FFCD 1201 phase II trial): result of single-arm, open-label phase II study [O] . O. Pellerin, S. Pernot, V. Vidal, 2019

机译：03:18 PM摘要104 Irinotecan药物洗脱珠子化疗（Debiri）加上MFOLFOX6作为结直肠癌不可切除肝脏常量转移患者的前线治疗（FFCD 1201期试验）：单臂，开放的结果-Label期II研究

Erratum to: The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer

著录项

引文网络

相似文献

相关主题

期刊订阅